Check­Mate-451: Bris­tol-My­ers’ Op­di­vo — plus Yer­voy — fails PhI­II com­bo lung can­cer study, the lat­est in a se­ries of set­backs

Bris­tol-My­ers Squibb $BMY is be­com­ing well prac­ticed at dis­ap­point­ing in­vestors with their R&D strat­e­gy for lung can­cer.

Af­ter the mar­ket closed Mon­day the phar­ma gi­ant re­port­ed that their Phase III tri­al match­ing Op­di­vo and their CT­LA-4 drug Yer­voy for Check­Mate-451 failed on the pri­ma­ry end­point for over­all sur­vival. Re­searchers were study­ing the com­bi­na­tion as a main­te­nance ther­a­py for small cell lung can­cer af­ter a first round of chemo, and this was one of the late-stage stud­ies that an­a­lysts have been wait­ing for.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.